Yumanity Therapeutics Inc
Change company Symbol lookup
Select an option...
YMTX Yumanity Therapeutics Inc
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
HSIC Henry Schein Inc

Company profile

Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

The symbol you entered, PTI, changed to YMTX.

Day's Change
0.09 (0.45%)
B/A Size
Day's High
Day's Low
(Below Average)

Today's volume of 30,042 shares is on pace to be lower than YMTX's 10-day average volume of 62,854 shares.

Latest Earnings Beat Consensus (Q3 ending 09/2020)Next Earnings Announcement
Announced November 16, 2020
-$2.20Q3 Consensus
of 3 analysts
-$3.60Difference from
Q4 Earnings
will announce
(Unconfirmed) March 9, 2021

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



YMTX's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.